DIRS.INFO The most relevant business & tech news

☆ Exclusive: Jacobs poised to merge government consulting unit with Amentum
▼ + stars: | 2023-11-16 | by ( David Carnevali | ) www.reuters.com time to read: +3 min

REUTERS/Joe Skipper/File Photo Acquire Licensing RightsNov 16 (Reuters) - Engineering consultant Jacobs Solutions Inc (J.N) is in advanced talks to merge its government consulting arm at a valuation of more than $4 billion with private equity-owned Amentum Services Inc, people familiar with the matter said on Thursday. Under the terms discussed, Amentum would merge with Jacobs' Critical Mission Solutions (CMS) business to create a new publicly traded company that would be majority-owned by Jacobs' shareholders, the sources said. Jacobs, Amentum, Lindsay Goldberg and American Securities did not immediately respond to requests for comment. The deal with Amentum would free up resources for Jacobs to focus on its people and places solutions division, which provides transportation and environmental consulting to government entities and private sector clients, and PA Consulting, a management consulting business advising across several sectors. Amentum provides technical and advisory services to government clients including the Air Force and NASA, as well as commercial clients such as ExxonMobil (XOM.N) and Caterpillar (CAT.N).

Persons: Joe Skipper, Amentum, Jacobs, Lindsay Goldberg —, Lindsay Goldberg, Robert Pragada, Artemis, Aecom, PAE, David Carnevali, Lisa Shumaker Organizations: Kennedy Space Center, REUTERS, Engineering, Solutions Inc, Amentum Services Inc, Jacobs, American Securities, NASA, PA Consulting, Air Force, ExxonMobil, Caterpillar, Thomson Locations: Cape Canaveral , Florida, U.S, New York

Political Cartoons View All 1244 Images“They ask questions but they don’t tell us what is going on,” Hawkins said of CMS. If trends continue, as many as 30 million people could end up being dropped from Medicaid once states finish reviewing their Medicaid rolls, according to Avalere's projections. The numbers dwarf the Biden administration’s initial projections that only 15 million people would lose coverage throughout the process. “We have to say it’s going poorly,” Massey Whorley, a principal at Avalere, said of the Medicaid redeterminations. Some Texas lawmakers have asked CMS to investigate issues in the state, where nearly 1 million have lost Medicaid.

Persons: Biden, Avalere, ”, Trevor Hawkins, Hawkins, “, ” Hawkins, they’ve, Xavier Becerra, Daniel Tsai, Tsai, Lily Mezquita, Mezquita, ” Massey Whorley, I’ve, Gavin Lesnick, Lesnick, Lynn Hearn, Hearn, We’ve, we’ve, ” Hearn, Mallory McManus, Cassidy Estes, Rogers, didn't, Estes, Graciela Camarena, Camarena, Jennifer Ruffcorn, Jennifer Wagner, ___ Hunter, Robert Wood Johnson Organizations: WASHINGTON, Medicaid, Legal Aid, Centers, Medicare, Services, CMS, Democratic, Human Services, HHS, CMS Center, Children’s Health Insurance, Biden, AP, state's Department of Human Services, Florida Health Justice, Florida Department of Children, Charlotte Center, Legal, Children's Defense Fund, Texas, Texas Health, Center, Budget, Associated Press Health, Science Department, Robert Wood Johnson Foundation Locations: Florida, Arkansas, Texas, Miami , Florida, Avalere, North Carolina, Atlanta

☆ Biden’s Race Against a Cure
▼ + stars: | 2023-11-13 | by ( The Editorial Board | ) www.wsj.com time to read: 1 min

Wonder Land: Citing the president’s age lets Democrats off the hook for the political failure of his economic policies. Images: AP/AFP/EPA/Getty Images Composite: Mark KellyThe Food and Drug Administration may soon approve two gene therapies with the potential to cure more than 100,000 Americans with debilitating sickle-cell disease. Gene therapies fix missing or defective genes. The one-time treatments have the potential to cure inherited disorders with early death sentences. The FDA has approved nine gene therapies for such diseases as Duchenne muscular dystrophy, spinal muscular atrophy and retinal dystrophy.

Persons: Mark Kelly The Organizations: AFP, EPA, Drug Administration, Medicare, Medicaid Services, FDA

Political Cartoons View All 1230 ImagesThe Montana State Hospital violates those laws and its patients' constitutional rights to dignity and due process, the lawsuit states. DiMauro, who suffered a traumatic brain injury in 2012, was admitted to the Montana State Hospital in September 2020. Staff also failed to treat a wound on his forehead that he suffered in a fall, the lawsuit states. Patzoldt, then 75, was admitted to the Montana State Hospital on Oct. 19, 2021, after having behavioral disruptions at a memory care center. A review of his records found his heart medication was not given to him for nearly three weeks in November 2021, the lawsuit states.

Persons: HELENA, Lucio DiMauro, David Patzoldt, Lesley Jungers, Greg Gianforte, Patzoldt, cellulitis Organizations: —, Montana State Hospital, Department of Public Health, Human Services, The Montana State Hospital, Staff, Medicare, Services Locations: Mont, Butte, Spokespeople, COVID, Montana

☆ UK financial watchdog urges banks to link bonuses with duty to clients
▼ + stars: | 2023-10-31 | by ( Huw Jones | ) www.reuters.com time to read: +2 min

Signage is seen for the FCA (Financial Conduct Authority), the UK's financial regulatory body, at their head offices in London, Britain March 10, 2022. The FCA said in a letter to chairs of banks' remuneration committees they should prioritise embedding the new Consumer Duty introduced in July, to ensure customers get fair value and appropriate products and services. "Senior managers and boards, especially those whose role is most relevant to the duty, are accountable for complying with the duty," the FCA said in the letter made public. Banks are currently deciding how to divide up the annual bonus pool as a cap limiting the size of bonuses, inherited from the European Union, expires. The watchdog said banks should ensure that there is a "clear, strong and evidenced link" between behaviours and overall pay, with "timely and transparent" adjustments when appropriate.

Persons: Toby Melville, Banks, Alasdair Steele, Huw Jones, Jan Harvey Organizations: FCA, Financial, Authority, REUTERS, Britain's, Consumer, European Union, CMS, Thomson Locations: London, Britain

☆ Wembanyama is a talent beyond compare, says Yao
▼ + stars: | 2023-10-25 | by ( Amy Tennery | ) www.reuters.com time to read: +1 min

NEW YORK, Oct 25 (Reuters) - France's Victor Wembanyama possesses a talent that defies comparison, retired great Yao Ming told Reuters, as the seven-foot four-inch (2.24-metre) rookie makes his highly anticipated National Basketball Association (NBA) regular-season debut on Wednesday. "I never see a big guy like, you know, (who) can do such a thing like he does," said Yao, an eight-times NBA All-Star who stands two inches (five cms) taller than Wembanyama. Yao spent his entire NBA career with the Houston Rockets and remains an iconic figure of Chinese sport after fuelling the popularity of the NBA in his home country. The Hall of Famer was reluctant to offer advice to Frenchman Wembanyama, who enters the NBA at a time of unprecedented international participation in the league. "He has his own expedition to go (on)," said Yao, who was travelling to New York as part of a some 30-person Chinese delegation this week.

Persons: Victor Wembanyama, Yao Ming, LeBron James, Yao, Frenchman Wembanyama, I'm, Amy Tennery, Echo Wang, Clare Fallon Organizations: Reuters, Basketball Association, San Antonio Spurs, Texan, Dallas Mavericks, NBA, Houston Rockets, Famer, Thomson Locations: New York

☆ US Private Equity Firms Challenge Amentum in Race for Jacobs Unit -Sources
▼ + stars: | 2023-10-04 | by ( Oct. | At P.M. | ) www.usnews.com time to read: +2 min

By David CarnevaliNEW YORK (Reuters) - U.S. buyout firms Veritas Capital and Platinum Equity are vying to acquire Jacobs Solutions Inc's government consulting business, competing against rival contractor Amentum, according to people familiar with the matter. Dallas-based Jacobs is seeking final offers this week for the unit, which is known as Critical Mission Solutions (CMS), and could be valued at more than $4 billion, the sources said. Veritas and Platinum Equity plan to make all-cash offers, while Amentum's private equity owners Lindsay Goldberg and American Securities intend to offer Amentum shares as part of their bid, the sources added. Veritas and Platinum Equity did not respond to requests for comment. These operations generated $10.5 billion in revenue in Jacobs' latest fiscal year.

Persons: David Carnevali, Amentum, Jacobs, Lindsay Goldberg, Robert Pragada, Artemis, Cynthia Osterman Organizations: Veritas Capital, Equity, Jacobs Solutions, Veritas, American Securities, CMS, NASA, PA Consulting Locations: Dallas, New York

☆ Drugmakers opt in to Medicare drug price negotiations – here's what happens next
▼ + stars: | 2023-10-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. All drugmakers of the first 10 medicines selected for Medicare drug price negotiations have agreed to participate in the talks, even after many of them sued to halt the process last month. The Centers for Medicare & Medicaid Services did not immediately respond to a request to confirm that all drugmakers agreed to the talks. President Joe Biden's Inflation Reduction Act, which passed last year, empowered Medicare to negotiate drug prices for the first time in the program's six-decade history. The pharmaceutical industry also argues that the process will threaten revenue growth, profits and drug innovation.

Persons: Joe Biden's, Boehringer Ingelheim, Johnson Januvia, Merck Farxiga, Novartis Enbrel, Amgen Imbruvica, AbbVie Stelara, Janssen, Bristol Myers, Biden Organizations: Pfizer Pharmaceuticals, CNBC, Medicare, Services, Sunday, Bristol Myers Squibb Jardiance, Johnson, Merck, AstraZeneca Entresto, Novartis, Novo Nordisk, U.S, CMS, Bristol, Bristol Myers Squibb Locations: Provo , Utah

U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. The ruling is the first to come from multiple lawsuits by drug companies and industry groups challenging the program. The drug price negotiation program is part of the Inflation Reduction Act, which Biden, a Democrat, signed last year. The Biden administration has repeatedly said there is nothing in the Constitution that prohibits drug price negotiations. Many other countries already negotiate drug prices.

Persons: Joe Biden, Jonathan Ernst, vindicating, Joe Biden's, Michael Newman, Biden, drugmakers, Newman, Karine Jean, Pierre, Donald Trump, Johnson, Januvia, Bristol Myers, Boehringer, Brendan Pierson, Nate Raymond, Costas Pitas, Alexia Garamfalvi, Bill Berkrot, Chris Reese, Leslie Adler Organizations: Social Security, University of Tampa, REUTERS, U.S, District, U.S . Chamber of Commerce, Medicare, Commerce, U.S . Justice, Republicans, Big Pharma, Republican, U.S . Centers, Medicaid Service, CMS, Bristol Myers Squibb, Pfizer, Johnson, Merck, Co's, Pharmaceutical Research, Manufacturers of America, Companies, Thomson Locations: Tampa , Florida, U.S, Dayton , Ohio, New York, Boston

☆ AstraZeneca, Boehringer Ingelheim to participate in Medicare drug price negotiations
▼ + stars: | 2023-09-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

AstraZeneca and Boehringer Ingelheim on Wednesday told CNBC they will agree to participate in the first round of Medicare drug price negotiations, even after both pharmaceutical companies sued to halt the process last month. AstraZeneca's Type 2 diabetes drug Farxiga and Boehringer Ingelheim's own diabetes drug Jardiance are among the first 10 drugs selected for price talks with Medicare. Manufacturers of the other eight drugs selected have until Oct. 1 to sign an agreement to participate in the process. The Inflation Reduction Act, which passed Congress last year in narrow party-line votes, empowered Medicare to negotiate drug prices for the first time in the program's six-decade history. The law is the central pillar in the Biden administration's efforts to control rising drug prices and was a major victory for the Democratic Party.

Persons: Farxiga, Boehringer Ingelheim, Boehringer, AstraZeneca, Biden Organizations: New, Halsted Pharmacy, AstraZeneca, Boehringer, Wednesday, CNBC, Medicare, Manufacturers, CMS, Centers, Services, Bristol Myers Squibb, Johnson, Merck, Chamber of Commerce, Democratic Party Locations: Chicago , Illinois

☆ Indian chemicals maker Epigral expects revenue from newer products to surge this year
▼ + stars: | 2023-09-21 | by ( Savio Shetty | ) www.reuters.com time to read: +2 min

Sept 21 (Reuters) - Indian chemicals maker Epigral (EPIG.NS) will keep diversifying its business and expects the share of revenue from new products to expand significantly this year, its chairman and managing director told Reuters on Thursday. At that time, we were catering to seven industries," Maulik Patel told the Reuters Trading India forum. The specialty chemicals market represents 22% of India's overall chemicals and petrochemicals market and is valued at $32 billion, according to KPMG. It exports its products to more than 20 countries including South Africa and the United States. (Join Trading India, a chat room hosted on Refinitiv Messenger: https://bit.ly/3TNDwkC)($1 = 83.0434 Indian rupees)Reporting by Savio Shetty; Editing by Sonia CheemaOur Standards: The Thomson Reuters Trust Principles.

Persons: Maulik Patel, Patel, Epigral, Savio Shetty, Sonia Cheema Organizations: Reuters, Reuters Trading, KPMG, Thomson Locations: Gujarat, Reuters Trading India, India, Ahmedabad, South Africa, United States

☆ Fall Covid shot rollout gets off to a bumpy start as some patients see insurance delays
▼ + stars: | 2023-09-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The rollout of a new round of Covid vaccines in the U.S. is off to a bumpy start as some patients report delays in health insurance coverage for the shots. Private insurance plans and government payers such as Medicare are required to cover the new jabs from Pfizer and Moderna , which became available late last week. It also comes after a huge shift in how Covid vaccines are covered in the U.S. Previously, the federal government purchased Covid vaccines directly from manufacturers at a discount to distribute to all Americans for free. Sarah Lindsey, an owner of a Florida-based jewelry store, called on her own insurer to add the new Covid shots to its formulary.

Persons: Sarah Lindsey, it's Organizations: Pfizer, Moderna, Medicare, Medicaid Services, CVS, U.S, CNBC Locations: U.S, Florida

The insurer said the rule, which would apply retroactively, was "arbitrary and capricious," and threatened "unpredictable consequences for Medicare Advantage organizations and the millions of seniors who rely on the Medicare Advantage program for their healthcare." Close to half of the approximately 65 million Medicare enrollees sign up for Medicare Advantage. Medicare Advantage plans differ from traditional Medicare because private companies offer them, and are reimbursed by the government for care. Though Humana is based in Louisville, Kentucky, it filed its lawsuit with the U.S. District Court in the Northern District of Texas. The case is Humana Inc et al v Becerra et al, U.S. District Court, Northern District of Texas, No.

Persons: Andrew Kelly, Humana, Biden, Xavier Becerra, District Judge Reed O'Connor, Becerra, Jonathan Stempel, Leroy Leo, Richard Chang Organizations: Humana Inc, REUTERS, U.S, overcharges, Medicare, Services, Jan, U.S . Department of Health, Human Services, CMS, Northern District of Texas, District, Fort, Affordable, Court, Northern District of, Thomson Locations: Queens , New York City, U.S, Louisville , Kentucky, Northern District, Northern District of Texas, New York, Bengaluru

☆ Judge withdraws from Medicare drug price case after stock ownership is revealed
▼ + stars: | 2023-09-01 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Ohio Governor Mike DeWine, right, shakes hands with Judge Thomas Rose of the U.S. District Court Southern District of Ohio after taking his oath of office, Monday, Jan. 14, 2019, in Cedarville, Ohio. A federal judge on Friday withdrew from a case that could block Medicare from negotiating over drug prices, just hours after a watchdog group revealed his ownership of stock in two pharmaceutical companies that would be directly impacted by the new program. He also owns Moderna stock worth between $15,000 and $50,000, the filing shows. The suit asked the court to rule that for Medicare to negotiate drug prices would be unconstitutional. Merck, Bristol Myers Squibb, Johnson & Johnson, Boehringer Ingelheim, AstraZeneca and the drugmaker lobby PhRMA have all filed complaints in different districts courts.

Persons: Mike DeWine, Judge Thomas Rose, Judge Thomas M, Rose, Biden, George W, Bush, Johnson, Boehringer Ingelheim, Robert Davis, Davis Organizations: U.S, District Court Southern District of Ohio, Southern, Southern District of Ohio, Johnson, AstraZeneca, Republican, Moderna, U.S . Chamber of Commerce, Department of Health, Human Services, Centers, Medicare, Merck, Bristol Myers Squibb, Court, Circuit Court Locations: Cedarville , Ohio, Southern District

☆ Ozempic could be the next target of Medicare drug price negotiations – here's why
▼ + stars: | 2023-08-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Ozempic, the blockbuster diabetes treatment from Novo Nordisk , could be next in line in the price negotiations between manufacturers and Medicare. Ozempic will likely be eligible for negotiations by the time the next round of drugs is selected in 2025, for price changes that will go into effect in 2027. Novo Nordisk's Rybelsus, a diabetes drug taken orally, could also be on the list because it contains the same active ingredient as Ozempic. A spokesperson for Novo Nordisk didn't directly comment on the potential for Ozempic to be included in the next round of talks. Medicare and private insurers typically secure discounts and rebates on the drugs they cover, but it's unclear how large they are.

Persons: Biden, Ozempic, Cantor Fitzgerald, Louise Chen, Elon Musk Organizations: Novo Nordisk, Pharmacy, Ozempic, CNBC, Novo Nordisk's Rybelsus, Medicare, Services, Elon Locations: Provo , Utah, U.S, Novo

☆ Medicare wants to cut the price on an Eli Lilly drug. What it means for LLY shares
▼ + stars: | 2023-08-30 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly's revenue from Jardiance — which it markets alongside privately held German biotech firm Boehringer Ingelheim — is likely to suffer due to Medicare negotiations. Compared to those growth drivers, Jardiance is a minor character in the Eli Lilly investment story. However, the deceleration is not entirely due to likely lower realized prices from Medicare negotiations. Eli Lilly looks "relatively protected" from early Medicare negotiations, BMO's Seigmerman said. Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023.

Persons: Eli Lilly, Biden, Myers Squibb, Johnson, Eli Lilly's, —, Evan Seigerman, Seigerman, BMO's Seigmerman, Lilly, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: pharma, Myers, Club, Johnson, Medicare, donanemab, Bank of America, FactSet, Mounjaro, Merck, Constitution, Wall Street, Bristol Myers Squibb, BMO Capital, CNBC, Services, drugmakers, and Drug Administration, FDA, Trulicity, Bloomberg, Getty Locations: Bristol, U.S, Indianapolis , Indiana

He said that once implemented, the prices on negotiated drugs will decrease for up to 9 million seniors who currently pay as much as $6,497 in out-of-pocket costs per year for these prescriptions. This kicks off the negotiation process for the 10 drugs whose new prices will go into effect in 2026. U.S. laws had prohibited Medicare from negotiating pharmaceutical prices as part of its prescription drug program that began about 20 years ago. CMS Director Dr. Meena Seshamani said Medicare plans to use a review process to make sure insurance companies keep clinically appropriate access to negotiated drugs. Two analysts said they expect the negotiated prices to move beyond Medicare and affect commercial markets for these drugs by 2026, when they come into effect.

Persons: Joe Biden, Jonathan Ernst, Biden, Joe Biden’s, Januvia, Xarelto, Johnson, Boehringer Ingelheim, Eli Lilly's, Jardiance, Mohit Bansal, Entresto, Eli Lilly, Merck, Bristol Myers, Giovanni Caforio, Caforio, enrollees, Meena Seshamani, Stelara, Amgen, Evan Seigerman, Patrick Wingrove, Mike Erman, Manas Mishra, Nandita Bose, Caroline Humer, Bill Berkrot Organizations: Social Security, University of Tampa, REUTERS, U.S, Bristol Myers Squibb, Pfizer, Merck, Co's, Johnson, Novo Nordisk, NYSE Arca Pharmaceutical, U.S . Centers, Medicare, Medicaid Services, Reuters Graphics Wells, Novartis, AstraZeneca, Bristol, J, U.S . Department of Health, Human Services, BMO Capital, Thomson Locations: Tampa , Florida, U.S, Amgen's, Jardiance, Germany, Bengaluru, Washington

☆ CMS Administrator on Medicare price negotiations: People will see benefits starting next year
▼ + stars: | 2023-08-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCMS Administrator on Medicare price negotiations: People will see benefits starting next yearCenters for Medicare and Medicaid Services Administrator Chiquita Brooks-Lasure joins 'Squawk Box' to discuss the Biden administration's unveiling of the first 10 drugs subject to Medicare price negotiations, how the list of drugs were chosen, and more.

Persons: Chiquita Brooks, Lasure Organizations: Medicare, Biden

☆ Explainer: Why the US is negotiating the price of 10 drugs
▼ + stars: | 2023-08-29 | by ( Patrick Wingrove | ) www.reuters.com time to read: +4 min

What are the Medicare drug price negotiations? The Medicare agency, known as the Centers for Medicare & Medicaid Services (CMS), was previously forbidden by law from bartering prices with manufacturers. The negotiations must end by Aug. 1, and Medicare will publish its list of new prices on Sept. 1. The process will begin again in February of 2025, when CMS selects another 15 costly prescription drugs for negotiations, with new prices on those going into effect in 2027. All the lawsuits seeking to avoid drug price negotiations argue that the new law is unconstitutional.

Persons: Joe Biden, Kevin Lamarque, Joe Biden’s, Patrick Wingrove, Bill Berkrot Organizations: Major Economies, White, REUTERS, U.S, Merck, Co's, Bristol Myers Squibb, Pfizer, Medicare, Medicaid Services, CMS, U.S . Chamber of Commerce, Thomson Locations: Energy, Washington , U.S

☆ Here are the 3 most-used drugs on the Medicare price negotiation list
▼ + stars: | 2023-08-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Bottles of the drug Jardiance, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo, Utah, January 9, 2020. Two blood thinners and a diabetes medication are the drugs most widely used by Medicare beneficiaries among a list of 10 drugs that will be subject to price negotiations between manufacturers and Medicare. The list names drugs with the highest spending for Medicare Part D, which covers prescription medications, for the period from June 1, 2022, to May 31, 2023. Nearly 1.6 million Medicare enrollees used Jardiance during the same time period, according to the fact sheet. Medicare Part D also spent more on those three drugs during the time period than it did on the seven other medicines on the list.

Persons: Eli Lilly, Biden, Myers Squibb, enrollees, Johnson Organizations: Company, U.S, Medicare, Myers, Centers, Services, Pfizer Locations: Provo , Utah, Bristol

☆ Biden administration unveils first 10 drugs subject to Medicare price negotiations
▼ + stars: | 2023-08-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +7 min

Fiasp and NovoLog, insulins made by Novo Nordisk The Medicare negotiations are the centerpiece of the Biden administration's efforts to rein in the rising cost of medications in the U.S. Drugmakers such as Merck and Johnson & Johnson and their supporters aim to derail the negotiations, filing at least eight lawsuits in recent months seeking to declare the policy unconstitutional. Drugmakers' legal challengesMerck, Johnson & Johnson, Bristol-Myers Squibb and Astellas Pharma are among the companies suing to halt the negotiation process. The suits make similar and overlapping claims that Medicare negotiations are unconstitutional. Biden and his top health officials have embraced the lawsuits as evidence that they're making progress in the fight to cut drug prices.

Persons: Biden, Joe Biden's, Boehringer Ingelheim, Johnson Januvia, Merck Farxiga, Novartis Enbrel, Amgen Imbruvica, AbbVie Stelara, Janssen, insulins, Johnson, Leigh Purvis, Drugmakers, drugmakers, Robert Davis Organizations: Bristol, Myers Squibb Jardiance, Johnson, Merck, AstraZeneca Entresto, Novartis, Novo Nordisk, Medicare, Centers, Services, Biden, AARP Public, Institute, Congressional, Office, Myers Squibb, Astellas Pharma, U.S . Chamber, Commerce, Supreme, Court, Circuit Court, Pharma, White, Big Pharma Locations: U.S, Bristol

A construction site of residential buildings by Chinese developer Country Garden is pictured in Tianjin, China August 18, 2023. The expected 0% year-on-year growth in home prices compared with a 1.4% gain tipped in the previous forecast in May, a Reuters poll of 12 economists conducted from Aug. 16-25 showed. "It is estimated that every one percentage point decline in property investment may drag down the GDP growth rate by 0.1 percentage points," said analyst Ma Hong at Zhixin Investment Research Institute. China observers are sceptical that the property sector could turn a corner in the near term despite Beijing's support measures. The government has suspended publishing data on youth unemployment, which has hit record highs in what analysts say is partly a symptom of regulatory crackdowns on big employers in real estate and other industries.

Persons: Tingshu Wang, Wang Xingping, Fitch Bohua, Ma Hong, Gao Yuhong, Xing Zhaopeng, Liangping Gao, Ryan Woo, Shuyan Wang, Shri Navaratnam Organizations: REUTERS, Fitch, Authorities, Zhixin Investment Research Institute, Thomson Locations: Tianjin, China, BEIJING

The IPO could come later this year or early next year, subject to market conditions, the sources added, requesting anonymity because the matter is confidential. The valuation attained will also be subject to market conditions, the sources added. EQT, CPPIB and Goldman Sachs declined to comment. The company develops payment software helping clients such as large hospital systems with the collection of bills from patients. The company now works with 1 million healthcare providers and handles more than 2.5 billion transactions annually, according to its website.

Persons: Goldman Sachs, Waystar, CPPIB, Echo Wang, David Carnevali, Stephen Coates Organizations: EQT, Plan Investment, Goldman Sachs Group Inc, JPMorgan Chase &, JPMorgan, Bain Capital, Fitch, Medicare, Medicaid Services, Thomson Locations: Canada, Navicure, New York

☆ Jefferies upgrades Eli Lilly as enthusiasm around weight-loss drugs grows following Wegovy study
▼ + stars: | 2023-08-09 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Jefferies is encouraged by recent results from a weight-loss drug study that could help lift Eli Lilly . Analyst Akash Tewari lauded the strong results from a recent trial study surrounding Novo Nordisk's weight loss drug Wegovy . Eli Lilly also raised its full-year guidance on Tuesday. Eli Lilly as added more than 42% upside from the start of the year. LLY YTD mountain Eli Lilly year to date — CNBC's Michael Bloom contributed to this report.

Persons: Jefferies, Eli Lilly, Akash Tewari, Wegovy, Tewari, Eli Lilly's, NVO, Michael Bloom

☆ Why this landmark cardiac study means a bigger market for Lilly's blockbuster weight loss drug
▼ + stars: | 2023-08-09 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

A landmark study of the cardiovascular benefits of weight loss drug Wegovy is being seen as a pivotal step toward broadening access to these drugs. The drug, also known as tirzepatide, is expected to be approved for weight loss by the Food and Drug Administration by year-end. Notably, Medicare does reimburse obese patients for weight loss surgery, but Mounjaro has been able to help patients realize an average weight loss that approaches the typical success of bariatric procedures. If CMS is able to reimburse patients for weight loss treatment that would significantly increase access, boosting sales. "This is the first time a weight [loss] medicinal intervention has shown to have cardiovascular risk reduction.

Persons: enrollees, Eli Lilly, Lilly, Akash Tewari, NVO, Tewari, Wells, Mounjaro, Mohit Bansal, Robert Califf, Goldman Sachs, Chris Shibutani, Shibutani, Goldman, Refinitiv, Morgan Stanley, comorbidities, Bansal Organizations: Nordisk's Ozempic, Centers for Disease Control, Food and Drug Administration, Jefferies, Medicare, Services, GLP, STAT, Goldman, Lilly, Novo Nordisk, BMI, Novo Locations: U.S, GLP, Tuesday's

Search resuls for: "CMS"

25 mentions found